Private equity firms are increasingly investing in cardiometabolic care (CMD) as GLP-1 weight-loss drugs gain traction and cardiovascular care shifts from hospitals to outpatient settings. CMD encompasses heart disease, stroke, diabetes, hypertension and liver conditions. Six notable deals include General Catalyst's $450m funding for Function Health, a personalized health testing platform in Austin, Texas.
ArchiMed completed a $1.1bn take-private of Esperion Therapeutics, a biopharma company in Ann Arbor, Michigan focused on cardiometabolic therapies. THL Partners-backed Headlands Research acquired Clinical Trials Research, a Sacramento-based clinical trial network. SK Capital-backed Spectrum Vascular acquired Piccolo Medical, a San Francisco medtech firm developing vascular navigation technology.
Resonetics bought Arcline-backed Resolution Medical, a Minnesota-based device manufacturer. River Glade Capital's Dynamic Access acquired Picc Stat, a Dallas-based vascular access services provider.
Source: PE Hub · Summarized by HeadlinesBriefing